FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants

FDA의 디프테리아 및 파상풍 독소와 세포외 백일해 항원, 간염 B (재조합), 그리고 소아마비 백신 혼합물 (PEDIARIX)의 유아 사용을 위한 허가

Published on
Journal: Morbidity and Mortality Weekly Report
[저자] Centers for Disease Control and Prevention (CDC)
[Category] 백일해, 파상풍,
Pubmed URL    DOI URL    
[Source] pubmed

On December 13, 2002, the U.S. Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), hepatitis B (HepB) (recombinant) and inactivated poliovirus vaccine (IPV), DTaP-HepB-IPV (PEDIARIX, SmithKline Beecham Biologicals, Rixensart, Belgium) for use in infants ages 2, 4, and 6 months. All components in the combined vaccine are recommended for routine use by the Advisory Committee on Immunization Practices (ACIP), the Committee on Infectious Diseases of the American Academy of Pediatrics, and the American Academy of Family Physicians. Combination vaccines decrease the number of vaccine injections.

All Keywords